NDAORALTABLET
Approved
Jun 1998
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
61
Data completeness
4/8 — Partial
Drug data last refreshed 15h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
MAXALT (rizatriptan benzoate) is an oral small-molecule triptan approved in 1998 for the acute treatment of migraine headaches. It works as a 5-HT1B/1D receptor agonist to reverse vasodilation and reduce neurogenic inflammation associated with migraine. The drug is available as an oral tablet and represents a foundational therapy in migraine management.
$0.001BPart D
LOE ApproachingDeclining
Product approaching loss of exclusivity with modest Part D utilization; brand teams should expect roster rationalization and defensive strategies.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (61)
Extension Study for Participants in Studies That Include Belzutifan (MK-6482-043/LITESPARK-043)
Started Mar 2026
450 enrolled
Von Hippel-Lindau DiseaseMalignant Neoplasms
Characterization, Health Resource Utilization and Biomarkers in Early-stage
Started Jan 2026
267 enrolled
Lung Cancer
A Clinical Study of Belzutifan and Zanzalintinib in People With Recurrent Kidney Cancer Following Adjuvant Therapy (MK-6482-033)
Started Nov 2025
904 enrolled
Renal Cell Carcinoma
Ceftolozane/Tazobactam Versus Meropenem for Febrile Neutropenia on Patients Colonized With or at Risk for Infection With Extended Spectrum Beta Lactamase - Producing Pathogens
Started Mar 2025
55 enrolled
Febrile Neutropenia
Supporting the National Expansion of HPV-based Cervical Cancer Screening in Tanzania Among Women Living With HIV
Started May 2024
2,000 enrolled
Cervical Cancer
Worked on MAXALT at Merck & Co.? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.